A Randomized, Double-Blind, Parallel, Nested Crossover Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2019
At a glance
- Drugs HM 12525A (Primary) ; Moxifloxacin
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Janssen Research & Development
- 06 Feb 2019 Planned primary completion date changed from 8 Nov 2018 to 5 Feb 2019.
- 06 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 16 Nov 2018 Planned End Date changed from 8 Nov 2018 to 5 Feb 2019.